Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Erythropoiesis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    95 result(s) found for: Erythropoiesis. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2009-015766-56 Sponsor Protocol Number: FER-AOC-MM Start Date*: 2009-12-02
    Sponsor Name:Vifor Pharma Inc.
    Full Title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with multiple myeloma and ir...
    Medical condition: Treatment of anaemic subjects with multiple myeloma and iron restricted erythropoiesis receiving chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10028228 Multiple myeloma LLT
    12.0 10049467 Erythropoiesis abnormal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003914-15 Sponsor Protocol Number: Studienprotokoll/V5.1/01.12.2013 Start Date*: 2014-06-17
    Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin III, Klin. Abteilung für Nephrologie und Dialyse
    Full Title: Continuos versus periodic intravenous iron supplementation in maintenance hemodialysis patients
    Medical condition: Anemia and iron deficiency in patients with end-stage renal disease on maintenance dialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004176-22 Sponsor Protocol Number: IMPURE-Study Start Date*: 2017-04-28
    Sponsor Name:Medizinische Universität Graz
    Full Title: IMProving Ultrafiltration and REmoval of uremic toxins by adapted automated peritoneal dialysis in a single center study (IMPURE-Study).
    Medical condition: Chronic kidney disease G5D
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011513-24 Sponsor Protocol Number: CC-5013-MDS-005 Start Date*: 2009-12-14
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID®) VERSUS PLACEBO IN SUBJECTS WITH TRANSFUSION...
    Medical condition: TRANSFUSION-DEPENDENT ANEMIA DUE TO IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES WITHOUT DELETION 5Q [31] AND UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENT
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) CZ (Completed) AT (Completed) IT (Completed) PT (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-001936-12 Sponsor Protocol Number: MD2014.01 Start Date*: 2019-02-11
    Sponsor Name:Sanquin Plasma Products BV
    Full Title: Efficacy and Safety of human apotransferrin in patients with β-thalassemia
    Medical condition: Beta thalassemia intermedia
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10054660 Thalassemia beta LLT
    20.1 100000004850 10062923 Thalassemia intermedia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004146-32 Sponsor Protocol Number: AFX01-13 Start Date*: 2008-02-27
    Sponsor Name:Affymax Inc.
    Full Title: AFX01-13: A Phase 3, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of AF37702 Injection for the Correction of Anemia in Patients with Chronic Renal Failur...
    Medical condition: Anaemia in Patients with Chronic Renal Failure (CRF) not on Dialysis and not on Erythropoiesis Stimulating Agent (ESA) Treatment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10058116 Nephrogenic anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed) HU (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002499-15 Sponsor Protocol Number: A536-04 Start Date*: 2012-12-19
    Sponsor Name:ACCELERON PHARMA INC
    Full Title: A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia
    Medical condition: β-thalassemia intermedia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10062923 Thalassemia intermedia LLT
    15.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2009-015767-14 Sponsor Protocol Number: FER-FID-CHEMO Start Date*: Information not available in EudraCT
    Sponsor Name:Vifor (International) AG
    Full Title: A randomised controlled parallel group open-label study to evaluate the efficacy and safety of intravenous ferric carboxymaltose versus no treatment in anaemic subjects with lymphoid malignancies...
    Medical condition: Anaemic subjects with lymphoid malignancies and functional iron deficiency receiving chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025631 Malignant lymphoid neoplasm NOS LLT
    14.0 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    14.0 10027433 - Metabolism and nutrition disorders 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002195-14 Sponsor Protocol Number: KPPM-Hx Start Date*: 2019-11-12
    Sponsor Name:University Hospital "Príncipe de Asturias"
    Full Title: Randomized clinical trial to assess the monocitary functionality and their relationship with the administration of intravenous iron in patient in hemodialysis according to practice guidelines or ac...
    Medical condition: Monocyte function in patients with anemia in hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    20.0 100000004848 10027884 Monocytes LLT
    20.1 100000004848 10005671 Blood monocytes normal LLT
    20.1 100000004848 10005669 Blood monocytes decreased LLT
    20.1 100000004848 10027881 Monocyte count low LLT
    20.1 100000004848 10027879 Monocyte count high LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002997-18 Sponsor Protocol Number: 53975 Start Date*: 2017-03-14
    Sponsor Name:University Medical Center Utrecht, the Netherlands
    Full Title: Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration
    Medical condition: Perinatal Arterial Ischemic Stroke (PAIS)
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003190-34 Sponsor Protocol Number: ACE-536-MDS-002 Start Date*: 2019-01-02
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, Open -label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Ris...
    Medical condition: Myelodysplastic syndrome (MDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10068361 MDS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-018718-57 Sponsor Protocol Number: REDERT Start Date*: 2010-06-17
    Sponsor Name:AZIENDA UNITA` SANITARIA LOCALE N 12 DI VIAREGGIO
    Full Title: Role of on-line hemodiafiltration (HDF) in the modulation of resistance to erythropoiesis stimulating agents (REDERT)
    Medical condition: patients on chronic hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014647 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000812-41 Sponsor Protocol Number: GFM-EPO-PRETAR Start Date*: 2017-12-29
    Sponsor Name:GFM-Groupe Francophone des Myélodysplasies
    Full Title: A RANDOMIZED TRIAL TESTING EARLY VERSUS LATE ONSET OF EPO ALFA TREATMENT IN LOWER RISK MDS WITH NON RBC TRANSFUSION DEPENDENT ANEMIA AND WITHOUT DEL 5Q
    Medical condition: Adult subject (18 years of age older) with low or intermediate-1 IPSS risk MDS with transfusions independent anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10028536 Myelodysplastic syndromes HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001253-23 Sponsor Protocol Number: 4202-ONC-203 Start Date*: 2022-09-23
    Sponsor Name:Forma Therapeutics, Inc.
    Full Title: A Phase 2 Open-Label Study to Evaluate Etavopivat for the Treatment of Anemia in Patients with Myelodysplastic Syndromes (MDS)
    Medical condition: Anemia of myelodysplastic syndromes (MDS), inherited hemolytic anemias, and other refractory anemias
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002270-39 Sponsor Protocol Number: 205270 Start Date*: 2018-02-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center, study in recombinant human erythropoietin (rhEPO) naïve non-dialysis participants with anemia associated with ...
    Medical condition: Anaemia associated with chronic kidney disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) PL (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2005-002218-39 Sponsor Protocol Number: AFX01-04 Start Date*: 2005-08-16
    Sponsor Name:Affymax, Inc.
    Full Title: A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of AF37702 Injection (HematideTM) in Chronic Kidney Diseas...
    Medical condition: Anaemia in patients with chronic kidney disease not on dialysis (pre-dialysis patients).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-013286-26 Sponsor Protocol Number: 002 Start Date*: 2010-04-29
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IIb, Randomized, Active Comparator-Controlled, Open-Label Clinical Trial to Study the Efficacy and Safety of MK-2578 for the Treatment of Anemia in ESA (Erythropoiesis-Stimulating Agent)-Na...
    Medical condition: Correction of anemia in ESA-naïve patients with chronic kidney disease (CKD) who are not on dialysis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003855-38 Sponsor Protocol Number: PIERAID-2013 Start Date*: 2014-09-26
    Sponsor Name:Miguel Giovanni Uriol Rivera
    Full Title: Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiv...
    Medical condition: Anaemia of inflammation in patients with chronic kidney disease on haemodialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001194-29 Sponsor Protocol Number: OSHO #075 Start Date*: 2008-01-11
    Sponsor Name:Universität Leipzig
    Full Title: An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy
    Medical condition: Patients with acute myeloid leukemia not eligible for or resistant to chemotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004889-10 Sponsor Protocol Number: DapaFIT Start Date*: 2021-04-28
    Sponsor Name:University Hospital Tuebingen
    Full Title: Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study
    Medical condition: Patients with T2DM and hypertension aged 40 to 70 years (including)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 17:00:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA